Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer
Conditions
Interventions
BNT323/DB-1303
Doxorubicin
+2 more
Locations
132
United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Broward Health Medical Center
Fort Lauderdale, Florida, United States
The Center of Hope Reno
Reno, Nevada, United States
Laura & Isaac Perlmutter Cancer Center
New York, New York, United States
Miami Valley Hospital South
Centerville, Ohio, United States
Ohio State University
Hilliard, Ohio, United States
Start Date
June 10, 2025
Primary Completion Date
March 1, 2028
Completion Date
November 1, 2029
Last Updated
April 24, 2026
NCT06257264
NCT06253494
NCT06547840
NCT05990426
NCT05489211
NCT04657068
Lead Sponsor
BioNTech SE
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions